UCB, Inc. v. Yeda Research and Development Co., Ltd.

E-Law Admin/ September 8, 2016/ Arzneimittelrecht Schweiz/ 0Kommentare

UCB, Inc. v. Yeda Research and Development Co., Ltd., 2015-1957

In an declaratory judgment requesting a declaration that plaintiff’s Cimzia brand antibody does not infringe defendant’s patent and that such patent is invalid, the district court’s grant of summary judgment of non-infringement is affirmed where, based on the specification and prosecution history, the monoclonal antibodies claimed in the patent are not infringed by the chimeric or humanized antibodies of the Cimzia product.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2016/09/08

Judges

Court

  • United States Federal Circuit

Counsel


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar